Brief: Harvard Bioscience Expects Fiscal 2023 Revenue To Be About Flat As Compared To 2022
07/11/2023 12:06
Nov 7 (Reuters) - Harvard Bioscience Inc HBIO.O :
* HARVARD BIOSCIENCE INC - EXPECT FISCAL 2023 REVENUE TO BE
ABOUT
FLAT AS COMPARED TO 2022
* HARVARD BIOSCIENCE INC - SEES 2023 ADJUSTED EBITDA MARGINS
IN
13% TO 14% RANGE
* HARVARD BIOSCIENCE INC - REMAIN ON PATH TO REDUCING NET
LEVERAGE
RATIO TO ABOUT 2X BY END OF YEAR
Source text for Eikon: ID:nGNX4r71ns
Further company coverage: HBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Harvard Bioscience
See all newsBrief: Harvard Bioscience Announces Creation Of Scientific Advisory Board
Harvard Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary
Harvard Bioscience Q2 revenue rises on telemetry demand, lifts 2026 outlook
Harvard Bioscience Inc expected to post a loss of 21 cents a share - Earnings Preview
Harvard Bioscience Q1 revenue falls, reaffirms 2026 guidance